2019
Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma
Baro M, Lopez Sambrooks C, Burtness BA, Lemmon MA, Contessa JN. Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics 2019, 18: 2124-2134. PMID: 31387891, PMCID: PMC6825559, DOI: 10.1158/1535-7163.mct-19-0163.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalCell Line, TumorCell ProliferationCell SurvivalCetuximabDrug Resistance, NeoplasmFemaleHead and Neck NeoplasmsHumansMiceNeuregulinsProto-Oncogene Proteins c-aktReceptor, ErbB-3Signal TransductionSquamous Cell Carcinoma of Head and NeckUp-RegulationXenograft Model Antitumor AssaysConceptsNeck squamous cell carcinomaSquamous cell carcinomaTherapeutic resistanceCell carcinomaResistant cellsConcentrations of cetuximabEFM-19 cellsCetuximab-resistant cellsActionable therapeutic targetsHNSCC cell linesTumor growth experimentsInhibition of EGFRErbB3 antibodyNeuregulin expressionOverall survivalTreatment regimensCetuximab resistanceTherapeutic targetAutocrine loopLocal controlTumor growthRadiotherapyEGFR inhibitionCetuximabNeuregulin Signaling
2013
Dysplasia at the margin? Investigating the case for subsequent therapy in ‘Low-Risk’ squamous cell carcinoma of the oral tongue
Sopka DM, Li T, Lango MN, Mehra R, Liu JC, Burtness B, Flieder DB, Ridge JA, Galloway TJ. Dysplasia at the margin? Investigating the case for subsequent therapy in ‘Low-Risk’ squamous cell carcinoma of the oral tongue. Oral Oncology 2013, 49: 1083-1087. PMID: 24054332, PMCID: PMC4037753, DOI: 10.1016/j.oraloncology.2013.08.001.Peer-Reviewed Original ResearchConceptsDisease-free survivalFox Chase Cancer CenterModerate dysplasiaOverall survivalLocal controlOral tongueSevere dysplasiaMild dysplasiaActuarial local controlInferior local controlKaplan-Meier methodOral tongue cancerWorse local controlSquamous cell carcinomaEarly-stage cancerAdditional therapyMeier methodResection marginsSubsequent therapyEntire cohortTongue cancerCancer CenterCell carcinomaPathology reportsFinal margins
2004
Sequence of Radiotherapy With Tamoxifen in Conservatively Managed Breast Cancer Does Not Affect Local Relapse Rates
Ahn PH, Vu HT, Lannin D, Obedian E, DiGiovanna MP, Burtness B, Haffty BG. Sequence of Radiotherapy With Tamoxifen in Conservatively Managed Breast Cancer Does Not Affect Local Relapse Rates. Journal Of Clinical Oncology 2004, 23: 17-23. PMID: 15545666, DOI: 10.1200/jco.2005.09.048.Peer-Reviewed Original ResearchConceptsConservative surgeryFree rateBreast cancerYale-New Haven HospitalSequence of radiotherapyLocal relapse rateCompletion of radiationBreast cancer patientsOverall survivalMargin statusNodal statusRelapse rateConcurrent administrationT stageRetrospective studyCancer patientsProgesterone statusPatientsStage ITamoxifenLocal controlConcurrent useCancer cellsSignificant differencesCancer